<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217723</url>
  </required_header>
  <id_info>
    <org_study_id>CBMTG 0801</org_study_id>
    <nct_id>NCT01217723</nct_id>
  </id_info>
  <brief_title>Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation</brief_title>
  <official_title>A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Canadian Blood and Marrow Transplant Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial for patients undergoing hematopoietic progenitor cell
      transplantation (HPCT) from an unrelated donor. Approximately 50% of the patients enrolled
      will receive Thymoglobulin® as part of the preparative regimen prior to HPCT. The other 50%
      of the patients enrolled will receive a standard preparative regimen. Thymoglobulin is known
      to suppress the types of cells that can cause a transplant complication known as &quot;chronic
      graft versus host disease (cGVHD)&quot;. The goal of this trial is to find out if adding
      Thymoglobulin to the preparative regimen will result in a decrease in cGVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a non-blinded, randomized, multicentre trial testing the effect of
      Thymoglobulin® vs. placebo on the primary outcome of cGVHD. Subjects will be children and
      adults having unrelated donor transplants.

      Intervention: Infusion of Thymoglobulin® on three days prior to the transplant.

      Hypothesis: The hypothesis is that the use of Thymoglobulin® in the experimental group will
      result in an absolute 20% increase in the number of patients free of cGVHD at 12 months, the
      time of peak incidence, from 20% in the control group to 40% in the experimental group.

      Outcome Measures: The Primary Outcome Measure is freedom from cGVHD at 12 months from
      transplantation, defined as withdrawal of all systemic immunosuppressive agents and without
      resumption up to 12 months (a binary end-point, yes/no). Secondary outcome measures: Quality
      of Life, overall incidence of cGVHD (including untreated cases and resolved cases), the
      incidence of &quot;extensive&quot; cGVHD, time to non-relapse mortality, time to all-cause mortality,
      time to relapse of leukemia, graft rejection or failure (Yes vs. No), serious infection (Yes
      vs. No), CMV activation (Yes vs. No), organ-specific grading of chronic graft versus host
      disease, resumption of immunosuppressive agents after 12 months (Yes vs. No), doses of
      immunosuppressive drugs still required at 12 months, and incidence of acute graft versus host
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Chronic GVHD</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>&quot;Freedom from Chronic GVHD&quot; is defined as withdrawal of all systemic immunosuppressive agents and without resumption up to 12 months (a binary endpoint, yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Measured at Screening, Month 6, 12 and 24</time_frame>
    <description>A series of questionnaires measured at the screening interval (up to 3 months prior to transplant), 6, 12 and 24 months post transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Thymoglobulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin (Rabbit)</intervention_name>
    <description>Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.</description>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>ATGr</other_name>
    <other_name>rabbit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)</intervention_name>
    <description>The standard preparative regimen can be myeloablative or reduced intensity.</description>
    <arm_group_label>No Thymoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The recipient has a hematologic malignancy

          -  The recipient will receive one of the specified preparative regimens

          -  The recipient will receive either a bone marrow (&quot;HPC, Marrow&quot;) or blood progenitor
             cell (&quot;HPC, Apheresis&quot;) graft

          -  The recipient has an unrelated donor who with high resolution typing is either fully
             MHC matched at HLA-A, B, C and DRB1 with the recipient or is 1-antigen or 1-allele
             mismatched at A, B, C or DRB1 loci The recipient meets the transplant centre's
             criteria for unrelated donor allogeneic transplantation , either myeloablative or
             non-myeloablative (syn. RIC).

          -  The recipient has good performance status (Karnofsky ≥60%)

          -  Recipient has given signed informed consent For the questionnaire component only, be
             able to complete the questionnaires in English or with a validated translation (as
             posted on the project website)

        Exclusion Criteria:

          -  The recipient is HIV antibody positive

          -  The recipient has a hypersensitivity to rabbit proteins or Thymoglobulin
             pharmaceutical excipients, glycine or mannitol

          -  The recipient has active or chronic infection (i.e. infection requiring oral or IV
             therapy)

          -  The recipient (if female and of childbearing potential) is pregnant or breast-feeding
             at the time of enrollment

          -  The recipient (if female and of childbearing potential) does not agree to use an
             adequate contraceptive method from the time of enrollment until a minimum of one year
             following transplant

          -  The recipient (if male and fertile) does not agree to use an adequate contraceptive
             method from the time of enrollment until a minimum of one year following transplant

          -  For the questionnaire component only, the recipient is unable to participate due to
             cognitive, linguistic or emotional difficulties (i.e. the recipient can participate in
             the main study but will be excluded from the questionnaire component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irwin Walker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster University, Faculty of Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly M Kerr, BA, BSN</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>63196</phone_ext>
    <email>hkerr@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine L Singh</last_name>
    <phone>604-875-411</phone>
    <phone_ext>69013</phone_ext>
    <email>csingh@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly M Kerr, BA, BSN</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>63196</phone_ext>
      <email>hkerr@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Catherine L Singh</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>69013</phone_ext>
      <email>csingh@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Nevill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Szwajcer, MD</last_name>
      <phone>204-787-4179</phone>
      <email>david.szwajcer@cancercare.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2YA</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Couban, MD</last_name>
      <phone>902-473-7006</phone>
      <email>stephen.couban@cdha.nshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital &amp; Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irwin Walker, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76384</phone_ext>
      <email>walkeri@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Tay, MD</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>73034</phone_ext>
      <email>jtay@toh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Kuruvilla, MD</last_name>
      <phone>416-946-4466</phone>
      <email>john.kuruvilla@uhn.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Enfant Jesus</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Genevieve Gallagher, MD</last_name>
      <phone>418-649-5727</phone>
      <email>genevieve.gallagher.cha@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Roy, MD</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>3404</phone_ext>
      <email>jroy.hmr@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gizelle Popradi, MD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31558</phone_ext>
      <email>gizelle.propardi@muhc.mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>L'Hotel Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Couture, MD</last_name>
      <email>felixcou@videotron.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Irwin Walker (Study Chair)</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>Acute leukemia (myeloid,lymphoid,or biphenotypic)</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Myeloproliferative disorder</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

